OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Birhiray on Advancing Clinical Trials in Oncology Using AI Tools and Tactics

September 29th 2025

Ruemu E. Birhiray, MD, discussed the advantages of using AI-based tools to enhance community-based clinical trials in oncology.

Dr Mulherin on Using AI to Address NGS Testing Barriers in Oncology Practice

September 28th 2025

Brian P. Mulherin, MD, discusses using AI tools to improve the implementation of NGS in community oncology practice.

Dr Wilfong on the Potential Use of AI Prediction Models to Improve Palliative Care in Oncology

September 28th 2025

Lalan Wilfong, MD, expands on the value of AI prediction models for consensus on patient prognosis and better end-of-life care in oncology.

Dr Flora on the Potential Role of AI in Clinical Trial Screening and Design for Oncology

September 28th 2025

Douglas Flora, MD, LSSBB, discusses how the use of artificial intelligence tools could improve patient screening and drug development in oncology.

Dr Mascarenhas on the IMpact-MF Trial of Imetelstat in R/R Myelofibrosis

September 26th 2025

John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.

Dr Vojnic on Vorasidenib in Grade 2 IDH1/2-Mutated Glioma

September 26th 2025

Morana Vojnic, MD, MBA, discusses vorasidenib in grade 2 IDH1/2-mutated glioma.

Dr Sherman on Advances in Surgical Brain Tumor Management

September 26th 2025

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses notable advances in the surgical management of patients with brain tumors.

Dr Dreyling on the Role of BTK Inhibitors in Frontline MCL

September 26th 2025

Martin Dreyling, MD, PhD, discusses the use of BTK inhibitors in frontline mantle cell lymphoma.

Dr Meisel on the Mechanism of Action of Palazestrant in ER+, HER2– Breast Cancer

September 26th 2025

Jane L. Meisel, MD, FASCO, discusses the mechanism of action of palazestrant in ER+, HER2– advanced/metastatic breast cancer.

Dr Ghia on the Implications of Data From CAPTIVATE for Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

September 26th 2025

Paolo Ghia, MD, provided insights into the significance of updated data from the final analysis of the phase 2 CAPTIVATE study in CLL/SLL.

Dr Mehnert on Next Steps for the Evaluation of Quadruplet Therapy in Advanced Melanoma

September 26th 2025

Janice M. Mehnert, MD, discusses the ongoing investigation of sarilumab plus ipilimumab, nivolumab, and relatlimab in unresectable stage III/IV melanoma.

Dr Khan on Key BTK Inhibitor Updates in Relapsed/Refractory CLL

September 26th 2025

Cyrus M. Khan, MD, discusses the key BTK inhibitor updates for the treatment of patients with relapsed/refractory CLL from the 2025 ASCO Annual Meeting.

Dr Strickler on the Rationale for Evaluating Temab-A in Chemo-Refractory Metastatic CRC

September 26th 2025

John H. Strickler, MD, details the impetus for evaluating the novel c-Met–directed ADC Temab-A in refractory metastatic colorectal cancer.

Dr Nathan on the Mechanism of Action of Roginolisib in Metastatic Uveal Melanoma

September 26th 2025

Paul Nathan, MBBS, PhD, MRCP, describes the mechanism of action of roginolisib and its ongoing evaluation in metastatic uveal melanoma.

Dr Beck on the FDA Approval of Subcutaneous Pembrolizumab in Solid Tumors

September 25th 2025

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab and berahyaluronidase for use across all adult and solid-tumor indications.

Dr Rischin on the Efficacy of Adjuvant Cemiplimab in High-Risk CSCC

September 24th 2025

Danny Rischin, MD, discusses key DFS data from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Dr Van Oekelen on the Role of S100A8/A9 in Promoting T-Cell Exhaustion in Multiple Myeloma

September 24th 2025

Oliver Van Oekelen, MD, PhD, discusses how S100A8/A9 in promotes T-cell exhaustion and limits responses to bispecific antibody therapy in multiple myeloma.

Dr Shitara on Satri-Cel in Advanced Gastric/GEJ Adenocarcinoma and Pancreatic Cancer

September 24th 2025

Kohei Shitara, MD, discusses efficacy data from a trial of the CAR T-cell therapy satri-cel in advanced gastric/ GEJ adenocarcinoma and pancreatic cancer.

Dr Raab on Teclistamab-Based Regimens in Newly Diagnosed Multiple Myeloma

September 24th 2025

Marc S. Raab, MD, discusses teclistamab for the treatment of patients with newly diagnosed multiple myeloma.

Dr Dotan on Gemcitabine and Nab-Paclitaxel in Treatment-Naive, Older Pancreatic Cancer

September 23rd 2025

Efrat Dotan, MD, discusses gemcitabine and nab-paclitaxel in treatment-naive, older patients with pancreatic cancer.